## James Larkin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/272595/publications.pdf Version: 2024-02-01



IAMES LADKIN

#	Article	IF	CITATIONS
1	Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. New England Journal of Medicine, 2011, 364, 2507-2516.	27.0	6,976
2	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New England Journal of Medicine, 2015, 373, 23-34.	27.0	6,773
3	Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. New England Journal of Medicine, 2012, 366, 883-892.	27.0	6,769
4	Pembrolizumab versus Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 2015, 372, 2521-2532.	27.0	4,838
5	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 2017, 377, 1345-1356.	27.0	3,589
6	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 2019, 381, 1535-1546.	27.0	2,484
7	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncology, The, 2015, 16, 375-384.	10.7	2,353
8	Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma. New England Journal of Medicine, 2014, 371, 1867-1876.	27.0	1,824
9	Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2019, 380, 1103-1115.	27.0	1,824
10	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. New England Journal of Medicine, 2017, 377, 1824-1835.	27.0	1,752
11	Renal cell carcinoma. Nature Reviews Disease Primers, 2017, 3, 17009.	30.5	1,727
12	Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. New England Journal of Medicine, 2014, 371, 1877-1888.	27.0	1,572
13	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. New England Journal of Medicine, 2018, 378, 1789-1801.	27.0	1,441
14	Adjuvant Dabrafenib plus Trametinib in Stage III <i>BRAF</i> -Mutated Melanoma. New England Journal of Medicine, 2017, 377, 1813-1823.	27.0	1,192
15	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet, The, 2015, 386, 444-451.	13.7	1,175
16	Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nature Genetics, 2014, 46, 225-233.	21.4	1,103
17	Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 1480-1492.	10.7	1,089
18	Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet, The, 2017, 390, 1853-1862.	13.7	1,032

#	Article	IF	CITATIONS
19	Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. Journal of Clinical Oncology, 2017, 35, 785-792.	1.6	930
20	Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncology, The, 2014, 15, 323-332.	10.7	890
21	Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2016, 17, 1248-1260.	10.7	832
22	Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncology, The, 2015, 16, 1473-1482.	10.7	762
23	Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncology, The, 2017, 18, 1009-1021.	10.7	716
24	Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal. Cell, 2018, 173, 581-594.e12.	28.9	609
25	Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin I²1/FAK Signaling. Cancer Cell, 2015, 27, 574-588.	16.8	485
26	Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell, 2021, 184, 596-614.e14.	28.9	485
27	Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. Journal of Clinical Oncology, 2017, 35, 226-235.	1.6	458
28	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. Journal of Clinical Oncology, 2022, 40, 127-137.	1.6	446
29	Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. Journal of Clinical Oncology, 2018, 36, 383-390.	1.6	431
30	Translational Implications of Tumor Heterogeneity. Clinical Cancer Research, 2015, 21, 1258-1266.	7.0	424
31	Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncology, The, 2018, 19, e447-e458.	10.7	376
32	Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. Journal of Clinical Oncology, 2017, 35, 3807-3814.	1.6	364
33	Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2020, 21, 1465-1477.	10.7	330
34	Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction. Cancer Cell, 2015, 27, 240-256.	16.8	299
35	Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo. JAMA Oncology, 2020, 6, 519.	7.1	287
36	Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. New England Journal of Medicine, 2020, 383, 1139-1148.	27.0	256

#	Article	IF	CITATIONS
37	Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncology, The, 2014, 15, 436-444.	10.7	242
38	Survival of patients with advanced metastatic melanoma: the impact of novel therapies–update 2017. European Journal of Cancer, 2017, 83, 247-257.	2.8	236
39	Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600–Mutant Stage III Melanoma. Journal of Clinical Oncology, 2018, 36, 3441-3449.	1.6	226
40	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 643-654.	10.7	224
41	Efficacy and Safety of Nivolumab in Patients With <i>BRAF</i> V600 Mutant and <i>BRAF</i> Wild-Type Advanced Melanoma. JAMA Oncology, 2015, 1, 433.	7.1	201
42	Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with longâ€term followâ€up of the randomized, openâ€label, phase 3 CheckMate 025 trial. Cancer, 2020, 126, 4156-4167.	4.1	201
43	Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. Journal of Clinical Oncology, 2020, 38, 3925-3936.	1.6	192
44	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncology, The, 2019, 20, e378-e389.	10.7	155
45	EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Annals of the Rheumatic Diseases, 2021, 80, 36-48.	0.9	153
46	Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. Journal of Clinical Oncology, 2021, 39, 2656-2666.	1.6	145
47	Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers. European Urology, 2014, 66, 936-948.	1.9	141
48	Survival of patients with advanced metastatic melanoma: The impact of novel therapies. European Journal of Cancer, 2016, 53, 125-134.	2.8	137
49	Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression. JAMA Oncology, 2017, 3, 1511.	7.1	131
50	Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell, 2021, 39, 1497-1518.e11.	16.8	126
51	Genome-wide association study identifies multiple risk loci for renal cell carcinoma. Nature Communications, 2017, 8, 15724.	12.8	106
52	Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. Lancet Oncology, The, 2016, 17, e4-e5.	10.7	103
53	Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution. Nature Communications, 2015, 6, 6336.	12.8	100
54	Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. European Journal of Cancer, 2020, 130, 126-138.	2.8	84

#	Article	IF	CITATIONS
55	Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology, 2021, 39, 1020-1028.	1.6	83
56	5-Year Outcomes with Cobimetinib plus Vemurafenib in <i>BRAF</i> V600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. Clinical Cancer Research, 2021, 27, 5225-5235.	7.0	82
57	Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives. Journal of the National Cancer Institute, 2016, 108, djv414.	6.3	81
58	Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial. Journal of Clinical Oncology, 2020, 38, 4064-4075.	1.6	78
59	Adjuvant Vascular Endothelial Growth Factor–targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. European Urology, 2018, 74, 611-620.	1.9	77
60	Health-related quality of life results from the phase III CheckMate 067 study. European Journal of Cancer, 2017, 82, 80-91.	2.8	76
61	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. European Journal of Cancer, 2015, 51, 833-840.	2.8	71
62	TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. Cancer Immunology Research, 2021, 9, 1202-1213.	3.4	71
63	Predictive biomarkers for response to immune checkpoint inhibition. Seminars in Cancer Biology, 2022, 79, 4-17.	9.6	70
64	Modeled Prognostic Subgroups for Survival and Treatment Outcomes in <i>BRAF</i> V600–Mutated Metastatic Melanoma. JAMA Oncology, 2018, 4, 1382.	7.1	65
65	Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. European Journal of Cancer, 2019, 116, 148-157.	2.8	64
66	Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600ÂE/K–mutant advanced or metastatic melanoma. European Journal of Cancer, 2019, 109, 61-69.	2.8	63
67	Escape from nonsense-mediated decay associates with anti-tumor immunogenicity. Nature Communications, 2020, 11, 3800.	12.8	61
68	Common variation at 2q22.3 (ZEB2) influences the risk of renal cancer. Human Molecular Genetics, 2013, 22, 825-831.	2.9	54
69	Prognostic score for patients with advanced melanoma treated with ipilimumab. European Journal of Cancer, 2015, 51, 2785-2791.	2.8	53
70	Epigenetic regulation in RCC: opportunities for therapeutic intervention?. Nature Reviews Urology, 2012, 9, 147-155.	3.8	51
71	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. Cell Reports, 2020, 31, 107550.	6.4	51
72	SnapShot: Renal Cell Carcinoma. Cell, 2015, 163, 1556-1556.e1.	28.9	50

#	Article	IF	CITATIONS
73	Extrinsic factors can mediate resistance to <scp>BRAF</scp> inhibition in central nervous system melanoma metastases. Pigment Cell and Melanoma Research, 2016, 29, 92-100.	3.3	44
74	An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors. Supportive Care in Cancer, 2020, 28, 561-570.	2.2	43
75	Clinical Models to Define Response and Survival With Anti–PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. Journal of Clinical Oncology, 2022, 40, 1068-1080.	1.6	43
76	Malignant Melanoma of the Gastrointestinal Tract: Symptoms, Diagnosis, and Current Treatment Options. Cells, 2021, 10, 327.	4.1	37
77	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 655-664.	10.7	37
78	Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067 Journal of Clinical Oncology, 2022, 40, 9522-9522.	1.6	37
79	Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma. Expert Opinion on Biological Therapy, 2016, 16, 389-396.	3.1	35
80	Efficacy of PD-1–based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma. European Journal of Cancer, 2019, 116, 207-215.	2.8	35
81	Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. European Journal of Cancer, 2018, 91, 168-170.	2.8	33
82	British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. The Lancet Gastroenterology and Hepatology, 2020, 5, 679-697.	8.1	33
83	RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. Contemporary Clinical Trials, 2021, 108, 106482.	1.8	33
84	Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor–Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial. Journal of Clinical Oncology, 2022, 40, 1929-1938.	1.6	33
85	Gene Expression Profiling in <i>BRAF</i> -Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib. Clinical Cancer Research, 2017, 23, 5238-5245.	7.0	32
86	Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with <i>BRAF</i> V600-mutated Metastatic Melanoma. Clinical Cancer Research, 2019, 25, 3239-3246.	7.0	32
87	Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era. Clinical Cancer Research, 2020, 26, 4201-4205.	7.0	30
88	Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study. Nature Ecology and Evolution, 2022, 6, 88-102.	7.8	30
89	Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis. Journal of Hepatology, 2021, 75, 177-189.	3.7	29
90	Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915). Cancer Research, 2021, 81, CT004-CT004.	0.9	28

#	Article	IF	CITATIONS
91	Axitinib for the Treatment of Metastatic Renal Cell Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 397-403.	1.3	23
92	Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 167.e17-167.e23.	1.6	22
93	Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered. European Urology, 2017, 71, 845-847.	1.9	22
94	PACMEL: A phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel. European Journal of Cancer, 2015, 51, 359-366.	2.8	21
95	Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design. Future Oncology, 2020, 16, 2165-2175.	2.4	20
96	Common Variation at 1q24.1 (ALDH9A1) Is a Potential Risk Factor for Renal Cancer. PLoS ONE, 2015, 10, e0122589.	2.5	19
97	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. European Journal of Cancer, 2021, 158, 156-168.	2.8	19
98	Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel GroupÂstudy. European Journal of Cancer, 2017, 80, 55-62.	2.8	18
99	Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. ESMO Open, 2020, 5, e000852.	4.5	18
100	Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. European Journal of Cancer, 2022, 165, 97-112.	2.8	18
101	PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma. BMC Cancer, 2019, 19, 1102.	2.6	17
102	Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab. , 2021, 9, e002742.		16
103	Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action. Expert Review of Anticancer Therapy, 2011, 11, 639-649.	2.4	14
104	Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy. Expert Review of Anticancer Therapy, 2017, 17, 647-655.	2.4	14
105	BMI and outcomes in melanoma: more evidence for the obesity paradox. Lancet Oncology, The, 2018, 19, 269-270.	10.7	14
106	The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials. Melanoma Research, 2021, 31, 181-185.	1.2	14
107	Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067. , 2021, 9, e003743.		14
108	Is advanced renal cell carcinoma becoming a chronic disease?. Lancet, The, 2010, 376, 574-575.	13.7	11

#	Article	IF	CITATIONS
109	Expanded access programmes: patient interests versus clinical trial integrity. Lancet Oncology, The, 2015, 16, 15-17.	10.7	10
110	Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma. British Journal of Cancer, 2021, 124, 237-246.	6.4	10
111	Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma: Evaluation of impact of prior anti-PD-1 therapy Journal of Clinical Oncology, 2021, 39, 9505-9505.	1.6	10
112	Challenging the Treatment Paradigm for Advanced Renal Cell Carcinoma: A Review of Systemic and Localized Therapies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e239-e247.	3.8	9
113	Contrast-Enhanced CT Density Predicts Response to Sunitinib Therapy in Metastatic Renal Cell Carcinoma Patients. Translational Oncology, 2017, 10, 679-685.	3.7	9
114	Efficacy of sequential treatment with sunitinib-everolimus in an orthotopic mouse model of renal cell carcinoma. Anticancer Research, 2012, 32, 2399-406.	1.1	9
115	External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer. Journal of Clinical Oncology, 2022, 40, 1772-1782.	1.6	9
116	Frequency of pathogenic germline variants in cancer susceptibility genes in 1336 renal cell carcinoma cases. Human Molecular Genetics, 2022, 31, 3001-3011.	2.9	9
117	CAcTUS: A parallel arm, biomarker driven, phase II feasibility trial to determine the role of circulating tumor DNA in guiding a switch between targeted therapy and immune therapy in patients with advanced cutaneous melanoma Journal of Clinical Oncology, 2021, 39, TPS9587-TPS9587.	1.6	8
118	The safety of nivolumab for the treatment of metastatic melanoma. Expert Opinion on Drug Safety, 2017, 16, 955-961.	2.4	7
119	Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591877742.	3.2	7
120	Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma. Expert Review of Anticancer Therapy, 2022, 22, 17-25.	2.4	7
121	Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma. Cancers, 2022, 14, 2300.	3.7	6
122	Sunitinib in Metastatic Renal Cell Carcinoma: A Systematic Review of UK Real World Data. Frontiers in Oncology, 2015, 5, 195.	2.8	5
123	Carbonic anhydrase IX in resected clear cell RCC. Nature Reviews Urology, 2015, 12, 309-310.	3.8	5
124	Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy. European Urology Focus, 2020, 6, 999-1005.	3.1	5
125	Association of health-related quality of life (HRQoL) and treatment safety with nivolumab (NIVO) in patients (pts) with resected stage IIIB/C or IV melanoma: Analysis of CheckMate 238 four-year follow-up (FU) data Journal of Clinical Oncology, 2021, 39, 9574-9574.	1.6	5
126	Pembrolizumab in the management of metastatic melanoma. Melanoma Management, 2015, 2, 315-325.	0.5	4

#	Article	IF	CITATIONS
127	Pazopanib-Induced Alopecia, an Underestimated Toxicity?. Frontiers in Oncology, 2015, 5, 112.	2.8	4
128	Effects of Molecular Heterogeneity on Survival of Patients With BRAFV600-Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM Study. JCO Precision Oncology, 2018, 2, 1-18.	3.0	4
129	Analysis of patients (pts) with in-transit metastases treated with nivolumab (NIVO) or ipilimumab (IPI) in CheckMate 238 Journal of Clinical Oncology, 2021, 39, 9569-9569.	1.6	4
130	Systemic anti-cancer therapy (SACT) dataset. Lancet Oncology, The, 2014, 15, 1063.	10.7	3
131	Relapse models for clear cell renal carcinoma. Lancet Oncology, The, 2015, 16, e376-e378.	10.7	3
132	The combination of vemurafenib and cobimetinib in advanced melanoma. Expert Opinion on Orphan Drugs, 2016, 4, 1105-1111.	0.8	3
133	Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy. Expert Review of Clinical Pharmacology, 2017, 10, 1-12.	3.1	3
134	Elevated Levels of <i>BRAF<sup>V600</sup></i> Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic Melanoma. JCO Precision Oncology, 2018, 2, 1-17.	3.0	3
135	Severe progressive scarring pembrolizumabâ€induced lichen planopilaris in a patient with metastatic melanoma. Australasian Journal of Dermatology, 2021, 62, 403-406.	0.7	3
136	CALYPSO: A three-arm randomized phase II study of durvalumab alone or with savolitinib or tremelimumab in previously treated advanced clear cell renal cancer Journal of Clinical Oncology, 2022, 40, LBA4503-LBA4503.	1.6	3
137	Individualising treatment choices in a crowded treatment algorithm. European Journal of Cancer, Supplement, 2013, 11, 160-168.	2.2	2
138	Anti-PD-1 monotherapy versus anti-PD1 plus anti-CTLA4 in advanced melanoma: how do we decide?. Melanoma Management, 2017, 4, 151-155.	0.5	2
139	PTU-009â€Upper gastrointestinal inflammation in patients with immune-checkpoint inhibitor induced diarrhoea. , 2018, , .		2
140	Metastatic melanoma: therapeutic agents in preclinical and early clinical development. Expert Opinion on Investigational Drugs, 2020, 29, 739-753.	4.1	2
141	Endocrinopathies induced by immune checkpoint inhibitors: the need for clear endocrine diagnosis. Lancet Oncology, The, 2021, 22, 905-907.	10.7	2
142	RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting. Contemporary Clinical Trials, 2021, 108, 106481.	1.8	2
143	Isolated imbalance due to bilateral vestibular failure following immune checkpoint inhibitor administration: two cases. European Journal of Cancer, 2021, 156, 187-189.	2.8	2
144	Abstract CT101: Phase III study of pembrolizumab (MK-3475) versus ipilimumab in patients with ipilimumab-naive advanced melanoma. , 2015, , .		2

#	Article	IF	CITATIONS
145	A Phase 1 first-in-human trial to evaluate the safety and tolerability of CCT3833, an oral panRAF inhibitor, in patients with advanced solid tumours, including metastatic melanoma Journal of Clinical Oncology, 2016, 34, TPS9597-TPS9597.	1.6	2
146	High-risk cutaneous melanoma follow-up: time for more intensive surveillance?. Melanoma Management, 2014, 1, 7-10.	0.5	1
147	Reply to â€~Comment on â€~Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''. British Journal of Cancer, 2017, 116, e15-e15.	6.4	1
148	PWE-025â€Microscopic colonic inflammation in immune check point inhibitor-induced diarrhoea/colitis. , 2018, , .		1
149	Reply to E. Hindié and K.R. Hess. Journal of Clinical Oncology, 2019, 37, 1356-1358.	1.6	1
150	Reply to E. Hindié. Journal of Clinical Oncology, 2021, 39, 944-946.	1.6	1
151	Abstract 964: Intra-tumor heterogeneity and Darwinian selection revealed by multi-region exome sequencing of renal cell carcinomas. , 2012, , .		1
152	Abstract LB-144: Modeling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance , 2013, , .		1
153	Abstract 4603: Intratumor heterogeneity in clear cell renal cell carcinoma (ccRCC): Multi-region sequencing redefines the mutational landscape of ccRCCs Cancer Research, 2013, 73, 4603-4603.	0.9	1
154	Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results >2,000 patients in 41 countries, with focus on older patients Journal of Clinical Oncology, 2022, 40, 306-306.	1.6	1
155	Advances in the Management of Metastatic Renal Cell Cancer. European Urology Supplements, 2009, 8, 758-761.	0.1	0
156	Advances in immunotherapy for melanoma. Melanoma Management, 2014, 1, 19-24.	0.5	0
157	Recent developments in melanoma management. Trends in Urology & Men's Health, 2016, 7, 8-12.	0.4	0
158	PNFLBA-16 FIRST RESULTS OF A-PREDICT: A PHASE II STUDY OF AXITINIB IN PATIENTS WITH METASTATIC RENAL CELL CANCER (RCC) UNSUITABLE FOR NEPHRECTOMY. Journal of Urology, 2017, 197, .	0.4	0
159	OP0165â€EULAR RECOMMENDATIONS FOR THE DIAGNOSIS AND THE MANAGEMENT OF RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS DUE TO CANCER IMMUNOTHERAPY. , 2019, , .		0
160	Avelumab and axitinib in the treatment of renal cell carcinoma: safety and efficacy. Expert Review of Anticancer Therapy, 2020, 20, 343-354.	2.4	0
161	Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC) Journal of Clinical Oncology, 2021, 39, 4547-4547.	1.6	0
162	Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results from the 2020 Global Patient Survey from 41 countries Journal of Clinical Oncology, 2021, 39, 4579-4579.	1.6	0

#	Article	IF	CITATIONS
163	Abstract 3404: Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma , 2013, , .		0
164	Abstract 1192: Establishment and characterization of a new patient-derived renal cell carcinoma xenograft panel. , 2014, , .		0
165	Malignant melanoma (metastatic). Clinical Evidence, 2008, 2008, .	0.2	0
166	Reply to T. Olivier et al. Journal of Clinical Oncology, 2022, , JCO2200209.	1.6	0
167	Abstract A012: Advanced melanoma exhibits a diversity of evolutionary routes to lethality. Cancer Research, 2022, 82, A012-A012.	0.9	0
168	Abstract PR002: Advanced melanoma exhibits a diversity of evolutionary routes to lethality. Cancer Research, 2022, 82, PR002-PR002.	0.9	0